Kepler Capital analyst Dariusz Ubik maintained a Sell rating on Alcon (ALC) on August 17 and set a price target of CHF50.00. The company’s shares closed last Wednesday at $59.84.
According to TipRanks.com, Ubik is ranked #5496 out of 6895 analysts.
Currently, the analyst consensus on Alcon is a Moderate Buy with an average price target of $64.41.
See today’s analyst top recommended stocks >>
Based on Alcon’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.84 billion and GAAP net loss of $57 million. In comparison, last year the company earned revenue of $1.82 billion and had a GAAP net loss of $109 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.